Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leg workout beats arm workout for gestational diabetes?

NCT ID NCT07554287

Disease control Sponsor: Lahore University of Biological and Applied Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if leg exercise (like pedaling) is better than arm exercise for controlling blood sugar, weight, and stress in pregnant women with gestational diabetes. 108 women in their second trimester will exercise three times a week for eight weeks. The goal is to find a safe, effective way to manage diabetes during pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female participants aged 18-35 years. 2. Gestational age 14-28 weeks (second trimester). 3. Singleton pregnancy (confirmed by obstetric record) only to avoid complications of multiple gestation. 4. Include both primigravida and multigravida (i.e., first or subsequent pregnancy). 5. Women with first time GDM in pregnancy. 6. Women with clinical diagnosis of gestational diabetes according to hospital/WHO criteria or hospital diagnostic test. 7. Blood glucose levels: Random capillary glucose \< 200 mg/dL at screening (to exclude overt diabetes) 8. Blood pressure: * Systolic BP \< 140 mmHg and Diastolic BP \< 90 mmHg (no confirmed gestational hypertension). * If BP ≥140/90 mmHg, confirm with repeat measurement 4 hours apart; exclude if persistent. 9. Willingness to participate and provide written informed consent. 10. Medically cleared by obstetrician to participate in moderate aerobic exercise. Exclusion Criteria: 1. Previous Cesarean section or medically indicated bed rest. 2. Known pre-existing diabetes mellitus (Type 1 or Type 2 prior to pregnancy). 3. Known major obstetric complications (e.g., placenta previa, severe pre- eclampsia). 4. Patients having multiple/twin/triplet pregnancies. 5. Known major fetal anomaly. 6. Anemic women with Hb \< 9 g/dL (excluded to prevent exercise intolerance). 7. Uncontrolled cardiovascular disease, musculoskeletal, or medical contraindications to exercise. 8. Psychiatric conditions severe enough to hinder informed consent. 9. Any other medical condition that, in the opinion of the obstetrician, makes participation unsafe.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes complication are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetes Complications gestational diabetes pregnancy disorder Pregnancy in Diabetics

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes complication Diabetes during pregnancy Gestational Gestational diabetes mellitus (GDM) Pregnancy complications Pregnancy in diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jinnah Hospital

    RECRUITING

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.